Oxygenta Pharmaceutical Limited, a prominent player in the pharmaceutical sector, has announced significant changes in its ownership structure and management. The company has received requests from four promoters seeking reclassification from the 'Promoter' category to the 'Public' category, signaling a potential shift in the company's control and governance.

Promoter Reclassification Requests

The four promoters who have submitted reclassification requests are:

1. Sai Sudhakar Vankineni: Holding 30,000 shares (0.08% of equity)
2. Snigdha Vankineni: Holding 5,43,000 shares (1.47% of equity)
3. Sumanth Simha Vankineni: Holding 3,43,700 shares (0.93% of equity)
4. Jhansi Rani Vankineni: Holding 26,000 shares (0.07% of equity)

In their applications, all four promoters have stated that they are not involved in the company's management, day-to-day affairs, or business operations. They have also confirmed that they do not have any rights to appoint directors or control management decisions.

Management Changes

Concurrent with the reclassification requests, Oxygenta Pharmaceutical has announced significant changes in its leadership:

1. Mr. Vankineni Sai Sudhakar has resigned from his positions as Managing Director and Chief Financial Officer, effective August 18, 2025.
2. Mr. Sanagari Kondal Reddy has stepped down from his role as Independent Director, also effective August 18, 2025.

Both resignations are attributed to changes in the ownership and management of the company, suggesting a broader restructuring effort.

Regulatory Compliance

Oxygenta Pharmaceutical has stated that it will undertake the necessary steps to comply with the reclassification process under SEBI regulations. The company will follow the procedures outlined in Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The promoters seeking reclassification have provided undertakings confirming their compliance with regulatory requirements, including:

• Not holding more than 10% of the total voting rights in the company
• Not exercising control over the company's affairs
• Not having special rights or shareholder agreements
• Not being represented on the board of directors
• Not acting as key managerial personnel

Market Implications

These developments at Oxygenta Pharmaceutical suggest a potential shift in the company's ownership structure and strategic direction. Investors and market watchers will be keenly observing how these changes might impact the company's future operations and performance.

As the pharmaceutical sector continues to evolve, Oxygenta Pharmaceutical's restructuring could position the company for new opportunities or challenges in the competitive landscape.

The company has not provided specific details about the incoming management or any potential changes in business strategy. Shareholders and stakeholders will likely await further announcements for more clarity on the company's future direction under its new leadership structure.

Oxygenta Pharmaceutical Limited, a subsidiary of Virupaksha Organics Limited, has announced significant changes in its top leadership following a change in ownership and management. The company, known for its ISO 9001:2015, ISO 14001:2018, and ISO 45001:2015 certifications, disclosed these developments in a regulatory filing to the BSE Limited.

Key Resignations

Vankineni Sai Sudhakar, who held the dual positions of Managing Director and Chief Financial Officer, has stepped down from both roles. Simultaneously, Sanagari Kondal Reddy has resigned from his position as an Independent Director. Both resignations are effective from August 18, 2025.

Reasons for Departure

According to the regulatory filing, both executives cited the change in ownership and management of the company as the primary reason for their resignations. In their respective resignation letters, both Sudhakar and Reddy confirmed that there were no other material reasons for their departures beyond the ownership transition.

Corporate Governance Compliance

The company's disclosure aligns with Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. Oxygenta Pharmaceutical has provided detailed information as required under the SEBI Master Circular dated November 11, 2024.

Management's Response

Balasubba Reddy Mamilla, Executive Director of Oxygenta Pharmaceutical Limited, signed the regulatory filing on behalf of the company. The management has requested the BSE to take the resignations on record.

Company Profile

Oxygenta Pharmaceutical Limited, with its registered office and factory in Sangareddy District, Telangana, is a certified pharmaceutical company. The firm's corporate office is located in Hyderabad, and it operates under the CIN: L24110TG1990PLC012038.

As the company navigates this transition in leadership, stakeholders will be watching closely to see how these changes impact Oxygenta Pharmaceutical's future direction and performance in the pharmaceutical sector.